Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 322 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Vancomycin hydrochloride Clear all

Conditions: Breast Cancer
Interventions: Tissue Expander (TE), Vancomycin and Gentamicin, Stimulan Rapid Cure; Procedure · Drug · Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Staphylococcus Aureus
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Bacterial Infections, Infection
Interventions: BC-3781, Vancomycin; Drug
Lead sponsor: Nabriva Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 9
States / cities: Chula Vista, California • La Mesa, California • Oceanside, California + 6 more

Conditions: Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Interventions: Bezlotoxumab, Standard CDI treatment; Biological · Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Advanced Non Small Cell Lung Cancer
Interventions: aerosolized aztreonam, aerosolized vancomycin, pembrolizumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Endocarditis, Bacterial, Infective Endocarditis
Interventions: daptomycin, vancomycin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Greenville, North Carolina • Cleveland, Ohio

Conditions: Skin and Subcutaneous Tissue Bacterial Infections, Skin Structures and Soft Tissue Infections
Interventions: delafloxacin, vancomycin, aztreonam; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 31
States / cities: Mobile, Alabama • Montgomery, Alabama • Anaheim, California + 28 more

Conditions: Infection of Total Knee Joint Prosthesis
Interventions: Bactisure; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: Los Angeles, California • Lexington, Kentucky • Louisville, Kentucky + 2 more

Conditions: Staphylococcus Aureus Bacteremia
Interventions: Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB), Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB); Drug
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 2,096 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 13
States / cities: Brighton, Colorado • Denver, Colorado • Grand Junction, Colorado + 10 more

Conditions: Osteoarthritis, Knee Infection, Prosthetic Joint Infection, Complications; Arthroplasty, Infection or Inflammation, Complications; Arthroplasty
Interventions: Static Spacer, Articulating Spacer; Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Total Knee Arthoplasty
Interventions: total knee arthroplasty, Tobramycin, Gentamicin, Antibiotic cement spacer; Procedure · Drug · Device
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Multi-Drug Resistant Organism
Interventions: Allogeneic Microbiota in Glycerol (10%) (AMG); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Shoulder Injuries
Interventions: Intervention - Intraosseous (IO) administration of vancomycin, Control - Standard IV administration of vancomycin; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diarrhea, Clostridium Difficile
Interventions: Tigecycline; Drug
Lead sponsor: Gary E. Stein, Pharm.D.; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: East Lansing, Michigan • Lansing, Michigan

Conditions: Clostridium Difficile Infection (CDI)
Interventions: Fidaxomicin, Vancomycin; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Ypsilanti, Michigan

Conditions: Sepsis, Sepsis Mrsa, Sepsis Bacteremia, Antimicrobial - Induced Nephropathy, Sepsis, Severe, Septic Shock, Septic Syndrome
Interventions: Multifaceted de-implementation strategy to reduce vancomycin overuse; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Enrollment: 52,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 1 more

Conditions: Prosthetic-joint Infection
Interventions: VT-X7 Treatment System, Two-stage exchange arthroplasty, SOC Antibiotics, Experimental Antibiotics; Combination Product · Procedure · Drug
Lead sponsor: Osteal Therapeutics, Inc.; Industry
Eligibility: 22 Years to 84 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 19
States / cities: Phoenix, Arizona • Los Angeles, California • Sarasota, Florida + 15 more

Conditions: Coronary Artery Disease
Interventions: GoodBelly Probiotic, Vancomycin; Dietary Supplement · Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 40 Years to 75 Years · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Milwauke, Wisconsin

Conditions: Acute Kidney Injury
Interventions: Blood sample; Procedure
Lead sponsor: Avera McKennan Hospital & University Health Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Multiple Sclerosis
Interventions: Vancomycin, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Infection, Hand Injury Wrist, Hand Injuries, Hand Injuries and Disorders, Hand Arthritis
Interventions: Systemic IV Vancomycin, Bier Block, Vancomycin; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Group B Streptococcal Infection
Interventions: Vaginal and rectovaginal swab cultures; Biological
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Moderate Clostridium Difficile Infection
Interventions: LFF571, Vancomycin (POC); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 14
States / cities: Palm Desert, California • Bristol, Connecticut • Clearwater, Florida + 11 more

Conditions: Ulcerative Colitis
Interventions: Fecal Microbiota Transplantation (FMT), OpenBiome, pretreatment antibiotics; Biological · Other
Lead sponsor: Najwa Elnachef; Other
Eligibility: 18 Years to 64 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement

Antimicrobial Drug Use and Resistant Staphylococcus Aureus

Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia

Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Evaluating Bactisure Wound Lavage in Orthopedic Wounds

Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

Articulating Versus Static Antibiotic Loaded Spacers for the Treatment of Prosthetic Knee Infection

Antibiotic Loaded Cement After TKA

Sentinel Cohort REACT

IO Vancomycin in TSA

Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)

A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections

Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis

A Second Trial of the Abbreviated Protocol Two-Stage Exchange

Effect of Probiotic Supplementation on Endothelial Function

Pharmacokinetics of Vancomycin in the ICU in Renal Replacement Therapy

Vancomycin Study in Multiple Sclerosis (MS)

Vancomycin Tissue Concentrations by Bier Block or Intravenous Administration

Intrapartum Effect of Vancomycin on Rectovaginal GBS Colonization

Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate Ulcerative Colitis